darzalex 100mg5ml concentrate for solution for infusion vials
janssen-cilag ltd - daratumumab - solution for infusion - 20mg/1ml
darzalex 400mg20ml concentrate for solution for infusion vials
janssen-cilag ltd - daratumumab - solution for infusion - 20mg/1ml
darzalex 20 mgml i.v
j-c health care ltd - daratumumab - concentrate for solution for infusion - daratumumab 20 mg / 1 ml - daratumumab - darzalex is indicated:• in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.• in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous st em cell transplant.• in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.• as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy
darzalex 20 mg/ml concentrate for solution for infusion
janssen pharmaceutica n.v., belgium - daratumumab - concentrate for solution for infusion - 20 mg/ml
darzalex 20 mg/ml concentrate for solution for infusion
janssen pharmaceutica n.v., belgium - daratumumab - concentrate for solution for infusion - 20 mg/ml
darzalex concentrate for solution for infusion 100mg5ml
johnson & johnson international (singapore) pte ltd - daratumumab - infusion, solution concentrate - daratumumab 20mg/ml
darzalex concentrate for solution for infusion 400mg20ml
johnson & johnson international (singapore) pte ltd - daratumumab - infusion, solution concentrate - daratumumab 20mg/ml
darzalex 120 mgml s.c. 1800 mg
j-c health care ltd - daratumumab - solution for injection - daratumumab 120 mg / 1 ml - daratumumab - darzalex is indicated:• in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.• in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.• in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.• as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
darzalex 100mg/5ml inj 100 mg/5ml
مستودع أدوية أداتكو - adatco drug store - daratumumab 100 mg/5ml - 100 mg/5ml
darzalex 400mg/20 ml inj 400 mg/20ml
مستودع أدوية أداتكو - adatco drug store - daratumumab 400 mg/20ml - 400 mg/20ml